Arcturus Therapeutics Q4 2023 Earnings Report $17.77 +0.85 (+5.02%) As of 02/21/2025 04:00 PM Eastern Earnings HistoryForecast Arcturus Therapeutics EPS ResultsActual EPS-$0.32Consensus EPS -$1.69Beat/MissBeat by +$1.37One Year Ago EPSN/AArcturus Therapeutics Revenue ResultsActual Revenue$33.99 millionExpected Revenue$64.14 millionBeat/MissMissed by -$30.15 millionYoY Revenue GrowthN/AArcturus Therapeutics Announcement DetailsQuarterQ4 2023Date3/7/2024TimeN/AConference Call ResourcesPress ReleaseARCT Earnings HistoryConference Call AudioYour browser does not support the audio element. Listen Now.Powered by Arcturus Therapeutics Earnings HeadlinesArcturus Therapeutics price target raised to $48 from $41 at BTIGFebruary 18, 2025 | markets.businessinsider.comArcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Receives $65.00 Consensus Target Price from BrokeragesFebruary 16, 2025 | americanbankingnews.comThe Real Hillbilly ElegyThe mountains of Appalachia are incredible to behold. Spanning thousands of miles across Alabama, Kentucky, Tennessee and beyond… It's one of our country’s most scenic areas. But hidden beneath the beauty is an ugly reality: our most beautiful land is also the poorest. It’s a tragedy because for over 200 years, generation after generation has worked “coal country” with nothing but a pick and shovel, hauling billions of dollars from the ground.February 22, 2025 | Porter & Company (Ad)CSL, Arcturus Therapeutics announce European Commission approval for KostaiveFebruary 14, 2025 | markets.businessinsider.comArcturus Therapeutics and CSL’s Kostaive COVID-19 vaccine approved in EuropeFebruary 14, 2025 | markets.businessinsider.comBreaking Down Arcturus Therapeutics: 5 Analysts Share Their ViewsFebruary 14, 2025 | benzinga.comSee More Arcturus Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Arcturus Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Arcturus Therapeutics and other key companies, straight to your email. Email Address About Arcturus TherapeuticsArcturus Therapeutics (NASDAQ:ARCT), a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA. The company is developing ARCT-810 (LUNAR-OTC), a mRNA-based therapeutic candidate, which is in Phase 2 clinical trial for treating ornithine transcarbamylase deficiency; and ARCT-154 (LUNAR-COV19), a mRNA vaccine candidate that is in Phase 3 arm of a Phase 1/2/3 study in Vietnam for the treatment of COVID-19, as well as ARCT-032 (LUNAR-CF), a mRNA therapeutic candidate for cystic fibrosis. Its product pipeline includes, ARCT-2301 for bivalent: ancestral/omicron which is in Phase 3; ARCT-2303 for monovalent that is in Phase 3; ARCT-2138 for quadrivalent which is in Phase 1; and LUNAR-FLU which is in pre-clinical trial. Arcturus Therapeutics Holdings Inc. was founded in 2013 and is headquartered in San Diego, California.View Arcturus Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles The Trade Desk Crashes on Earnings, But Growth Catalysts PersistHims & Hers Earnings Could Be a Game Changer—What to Do NowAnalysts See Buying Opportunity in NVIDIA Before EarningsAirbnb's Earnings: Sky High Results, Grounded Guidance?Is Coinbase Stock a Buy After Earnings?CVS Health: Earnings Beat Ignites Stock RallyQualcomm’s Post-Earnings Dip: A Prime Buying Opportunity? Upcoming Earnings Workday (2/24/2025)Intuit (2/25/2025)American Tower (2/25/2025)Bank of Montreal (2/25/2025)Bank of Nova Scotia (2/25/2025)Public Storage (2/25/2025)NVIDIA (2/26/2025)Synopsys (2/26/2025)Salesforce (2/26/2025)Lowe's Companies (2/26/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
